Johnson & Johnson (NYSE:JNJ) – Analysts at Jefferies Group boosted their FY2017 earnings estimates for Johnson & Johnson in a report issued on Friday. Jefferies Group analyst J. Holford now expects that the company will earn $7.29 per share for the year, up from their prior forecast of $7.27. Jefferies Group has a “Buy” rating and a $160.00 price target on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s Q4 2017 earnings at $1.73 EPS, FY2019 earnings at $8.93 EPS, FY2020 earnings at $9.63 EPS, FY2021 earnings at $10.50 EPS and FY2022 earnings at $11.40 EPS.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter last year, the company earned $1.68 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year.

A number of other research firms have also recently weighed in on JNJ. Citigroup raised their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price objective on the stock. in a report on Monday. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. BMO Capital Markets raised their price objective on shares of Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Finally, Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $145.52.

Shares of Johnson & Johnson (JNJ) opened at $141.89 on Monday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $144.35. The firm has a market cap of $381,190.00, a P/E ratio of 24.63, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.37%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its position in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after buying an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC grew its position in Johnson & Johnson by 717.9% in the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after buying an additional 3,289,763 shares during the last quarter. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after buying an additional 3,023,110 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in Johnson & Johnson by 47.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after buying an additional 2,581,562 shares during the last quarter. Finally, Stifel Financial Corp grew its position in Johnson & Johnson by 6,715.9% in the 3rd quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock valued at $334,777,000 after buying an additional 2,534,918 shares during the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Analysts Offer Predictions for Johnson & Johnson’s FY2017 Earnings (JNJ)” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/analysts-offer-predictions-for-johnson-johnsons-fy2017-earnings-jnj/1799341.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.